Shopping Cart
- Remove All
- Your shopping cart is currently empty
Reltecimod (AB-103) TFA is an antagonist of the T-cell-specific surface glycoprotein CD28 (TP44), demonstrating efficacy against various bacterial infections, including exotoxins, endotoxins, and ionizing radiation. By modulating the inflammatory response through attenuation of the key CD28/B7-2 co-stimulatory pathway without full inhibition, Reltecimod TFA is utilized in researching necrotizing soft-tissue infections (NSTIs) [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $30 | 5 days |
Description | Reltecimod (AB-103) TFA is an antagonist of the T-cell-specific surface glycoprotein CD28 (TP44), demonstrating efficacy against various bacterial infections, including exotoxins, endotoxins, and ionizing radiation. By modulating the inflammatory response through attenuation of the key CD28/B7-2 co-stimulatory pathway without full inhibition, Reltecimod TFA is utilized in researching necrotizing soft-tissue infections (NSTIs) [1]. |
In vivo | Reltecimod, administered intravenously at dosages ranging from 1.25 to 5 mg/kg, has been shown to enhance survival rates in mice infected with various bacteria [1]. |
Alias | AB-103 TFA |
Molecular Weight | 1037.19 (free base) |
Formula | C46H72N10O15S.xC2HF3O2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.